Search results
Moderna’s Covid-19 vaccine meets primary efficacy endpoint in Phase III trial
Clinical Trials Arena via Yahoo Finance· 6 days agoModerna has announced that its Phase III clinical trial of the investigational next-generation Covid...
Moderna says next-generation COVID vaccine efficacy non-inferior to current shot
Reuters via Yahoo News· 7 days agoThe experimental vaccine, which met the main trial goal, was being tested in more than 11,000 people...
Moderna Announces Positive Phase 3 Efficacy Data for mRNA-1283, the Company’s Next Generation COVID-...
The Joplin Globe· 7 days agomRNA-1283 met its primary vaccine efficacy endpoint in a Phase 3 trial, demonstrating non-inferior vaccine efficacy against COVID-< ...
Moderna says next-gen COVID shot effective in study
BioPharma Dive via Yahoo Finance· 7 days agoTrial data suggest the shot — an important component of an upcoming combination inoculation — has proven at least as effective, and in some cases...
Moderna says new-generation COVID vaccine more effective than Spikevax in adults 18 and over
Morningstar· 6 days agoModerna Inc. said Thursday a Phase 3 trial of its next-generation COVID-19 vaccine met its main goal and showed higher ...
Moderna's mRNA-1283 vaccine shows promise in Phase 3 trial By Investing.com
Investing.com· 7 days agoModerna , Inc. (NASDAQ:MRNA) has announced successful results from the Phase 3 trial of its...
Moderna Just Gave Investors Another Reason to Buy the Stock
The Motley Fool via AOL· 4 days agoCOVID-19 vaccine and its investigational flu vaccine. mRNA-1083 knocked it out of the park in the...
Moderna Stock Soars on Cutting-Edge Personalized Cancer Vaccines | Investing.com
Investing.com· 3 days agoStocks Analysis by MarketBeat.com (Jea Yu) covering: Merck & Company Inc, Amgen Inc, Biogen Inc,...
Gateway - Quartz
Quartz· 1 day agoNovo Nordisk responded this week to the Federal Trade Commission’s (FTC) suggestion that it filed ‘junk’ patents to prevent competition and raise prices. Moderna stock surged ...
Moderna (NASDAQ:MRNA) Stock Price Down 2.2% on Insider Selling
ETF DAILY NEWS· 6 days agoShares of Moderna, Inc. (NASDAQ:MRNA – Get Free Report) traded down 2.2% during mid-day trading on Wednesday following insider selling activity. 392,597 shares changed hands ...